雖然這篇Finerenone鄉民發文沒有被收入到精華區:在Finerenone這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Finerenone是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Effect of Finerenone on Chronic Kidney Disease Outcomes in ...
Abstract · Background. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2第二型糖尿病腎病變患者使用Finerenone的腎臟與心血管保護 ...
Finerenone 是第一個非類固醇類礦物皮質素受體拮抗劑(Nonsteroidal mineralocorticoid receptor antagonist )。在去年10月線上發表於新英格蘭醫學 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3finerenone降低慢性腎臟、糖尿病患者心血管風險14% - 環球生技
Finerenone 是一種新型非類固醇礦物皮質(mineralocorticoid)激素受體拮抗劑,能夠阻斷在多個組織中的礦物皮質受體過度活化,這與腎臟和心臟損傷有關。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Finerenone - Wikipedia
Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Finerenone : third-generation mineralocorticoid receptor ...
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease · Authors · Affiliation.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Finerenone and Cardiovascular Outcomes in Patients With ...
The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) investigated the effects of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7US FDA approves finerenone for the treatment of patients with ...
Finerenone is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Finerenone for Patients With CKD and Type 2 Diabetes
Finerenone for Patients With CKD and Type 2 Diabetes ... Finerenone reduced the risks of chronic kidney disease (CKD) progression and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Finerenone benefits patients with diabetes across spectrum of ...
The nonsteroidal mineralocorticoid receptor antagonist finerenone has been evaluated in two trials of patients with chronic kidney disease and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Finerenone in predominantly advanced CKD and T2D with or ...
Abstract. FIDELIO-DKD investigated the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone in patients with chronic kidney ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Finerenone - an overview | ScienceDirect Topics
Finerenone decreased biomarkers of heart failure to a similar degree as spironolactone and was associated with less hyperkalemia and less renal function ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Finerenone: MedlinePlus Drug Information
Finerenone is used to treat adults with chronic kidney disease (damage to the kidneys which may worsen over time and may cause the kidneys ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13The RALES Legacy and Finerenone Use on CKD Patients
This double-blind, placebo-controlled trial evaluated the effects of the “novel” mineralocorticoid receptor antagonist—finerenone—on kidney and cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Finerenone ushers 'exciting time' at the crossroads of cardio ...
In July, the FDA approved the mineralocorticoid receptor inhibitor antagonist finerenone (Kerendia, Bayer) for lowering risk for kidney and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Kerendia (finerenone) dosing, indications, interactions ...
Medscape - Chronic kidney disease dosing for Kerendia (finerenone), frequency-based adverse effects, comprehensive interactions, contraindications, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Efficacy and Safety of Finerenone in Subjects With Type 2 ...
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD) · For at least 4 weeks prior to the run-in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Finerenone Reduces New-Onset Atrial Fibrillation in Patients ...
Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Finerenone: Fiddling With Hyperkalemia? - American Journal ...
Finerenone was recently approved by the US Food and Drug Administration for treatment of diabetic kidney disease (DKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Cardiovascular Effects of Finerenone, a New ...
Finerenone (Kerendia) is a nonsteroidal mineralocorticoid-receptor antagonist; it reportedly has more anti-inflammatory and antifibrotic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Cardiovascular and kidney outcomes with finerenone in ...
Cardiorenal outcomes, Chronic kidney disease, Finerenone, Hospitalization for heart failure, Hyperkalaemia, Type 2 diabetes. Topic:.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Finerenone in Reducing Kidney Failure and Disease ...
The FIDELIO-DKD trial showed that finerenone has salutary effects on CV and renal outcomes among patients with T2DM and CKD, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Design and Baseline Characteristics of ... - Karger Publishers
Methods: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial aims to assess the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Finerenone Reduces CV Outcomes in Patients With Early ...
The study, when coupled with FIDELIO-DKD, now opens up finerenone to ... 2 diabetes and mild-to-moderate renal disease, finerenone (Bayer ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Dr Bertram Pitt: Finerenone Works Across the Spectrum of ...
Now, finerenone is a nonsteroidal mineralcorticoid receptor antagonist [MRA]. And as a mineralcorticoid receptor antagonist, you would expect ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Finerenone - Bayer HealthCare Pharmaceuticals - AdisInsight
Finerenone is a next-generation, nonsteroidal, oral inhibitor of the mineralocorticoid receptor (MR) developed by Bayer Healthcare Pharmaceuticals, for the.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Finerenone: A Potential Treatment for Patients with Chronic ...
Moreover, new and ongoing trials have demonstrated that the selective nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Finerenone Receives FDA Approval for Treatment of Chronic ...
Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained estimated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Finerenone | ≥99%(HPLC) - Selleck Chemicals
Finerenone (BAY 94-8862) is a highly selective, and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Fi.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29KERENDIA (finerenone) to Treat CKD Associated with Type 2 ...
KERENDIA® (finerenone) is a first-in-class, nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the progression of chronic kidney ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Finerenone Attenuates Endothelial Dysfunction and ... - Frontiers
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Raquel ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31CV benefits of finerenone in T2DM and CKD - Nature
Finerenone, a non-steroidal mineralocorticoid-receptor antagonist, has previously been shown in the FIDELIO-DKD trial to reduce the risk of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32215341s000lbl.pdf - Accessdata.fda.gov
Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure [see. Clinical Pharmacology (12.3)], which may increase the risk of Kerendia ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Finerenone for treating chronic kidney disease in people with ...
Suggested remit: To appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating chronic kidney disease in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Finerenone | Clinical Diabetes
Finerenone is a selective mineralocorticoid receptor (MR) antagonist being studied for its potential in reducing cardiovascular and renal adverse outcomes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Finerenone: Uses, Interactions, Mechanism of Action - DrugBank
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist indicated to lower the risk of eGFR decline, end stage kidney disease, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36DKD treatment update: SGLT2 inhibitors and finerenone
Ian de Beor joins primary care physician Amrit Lamba to discuss how the recent approval finerenone and extension of the dapagliflozin label ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Finerenone Using Asymmetric Transfer Hydrogenation - Wiley ...
Abstract (−)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Finerenone (Kerendia®) - Straight Healthcare
Two large studies have looked at the effects of finerenone on clinical outcomes in patients with type 2 diabetes and chronic kidney disease. The first study ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Finerenone Uses, Side Effects & Warnings - Drugs.com
Finerenone is used in adults with chronic kidney disease related to diabetes mellitus type 2, to reduce the risk of:.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Finerenone (Oral Route) Description and Brand Names
Finerenone is used to lower the risk of serious kidney and heart problems (eg, kidney function decline, end-stage kidney disease, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41finerenone | Ligand page - IUPHAR/BPS Guide to ...
Comment: Finerenone (BAY 94-8862) is a next generation (first-in-class) oral, non-steroidal mineralocorticoid receptor antagonist which blocks the deleterious ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42Efficacy and safety of finerenone in patients with chronic ...
Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Bayer's Finerenone Meets Primary Endpoint in Phase III ...
Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Finerenone Reduces CV Issues in T2D Patients With ...
In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, the drug improved kidney ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Finerenone significantly reduced renal and ... - Newswire.ca
Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Cardiovascular Outcomes With Finerenone in Patients With ...
Scirica: FIDELIO-DKD was a study with a drug called finerenone, which is a selective, nonsteroidal, mineralocorticoid receptor antagonist. So, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Finerenone NDA Submitted for Diabetic Kidney Disease - MPR
A New Drug Application has been submitted for finerenone for the treatment of chronic kidney disease in patients with type 2 diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Finerenone improves outcomes in patients with mild-to ...
The FIDELIO-DKD trial previously reported that finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), slowed progression of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49FDA Approves Finerenone for Patients with CKD and Type 2 ...
Finerenone was shown to reduce risk for kidney decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Bayer faces an uphill fight with finerenone - Evaluate Pharma
Such is the conclusion from the Fidelio-DKD trial of Bayer's finerenone in diabetic kidney disease: the mineralocorticoid receptor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Finerenone Drug Found to Delay Diabetic Kidney Disease ...
Investigational drug finerenone had stable renal and cardiovascular benefits for patients with chronic kidney disease and type 2 diabetes, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Study Suggests Bayer's Finerenone Slows CKD Progression ...
Findings from a recently published Phase III study show that Bayer's nonsteroidal antimineralocorticoid drug, finerenone, slowed progression ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Kerendia (Finerenone Tablets): Uses, Dosage, Side Effects ...
Kerendia (Finerenone Tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Bayer's finerenone gets FDA nod for diabetic kidney disease -
FDA approves Bayer's first-in-class MR antagonist finerenone as Kerendia for chronic kidney disease (CKD) in people with type 2 diabetes, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Finerenone Cuts Kidney, Heart Risks in CKD and T2D
In FIDELIO-DKD, we hypothesized that the MR antagonism with finerenone would slow kidney disease progression and reduce cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Finerenone Oral: Uses, Side Effects, Interactions ... - WebMD
Find patient medical information for finerenone oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Biotransformation of Finerenone, a Novel Nonsteroidal ...
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58The novel mineralocorticoid receptor antagonist finerenone ...
In vivo, oral application of finerenone resulted in an accelerated re-endothelialization 3 days following electric injury of the murine carotid ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Finerenone Prices, Coupons & Savings Tips - GoodRx
Compare prices, print coupons and get savings tips for Finerenone (Kerendia) and other Kidney Disease drugs at CVS, Walgreens, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Bayer's near-approval Farxiga rival meets goal in 2nd phase 3
Bayer's finerenone has met the primary endpoint in another phase 3 clinical trial. The study, which linked the mineralocorticoid receptor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Finerenone: third-generation mineralocorticoid receptor ...
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62[護理新知] JAMA:Finerenone可有效緩解糖尿病腎病變 ...
Finerenone 是一種新型非類固醇礦物性皮質激素受體拮抗劑(mineralocorticoid receptor antagonist, MRA),體外試驗顯示,Finerenone比spironolactone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63Effets cardiovasculaires de la finerenone chez les patients ...
Background: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64BRIEF-Bayer's Finerenone Meets Primary Endpoint In Phase ...
BAYER'S FINERENONE MEETS PRIMARY ENDPOINT IN PHASE III FIDELIO-DKD RENAL OUTCOMES STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65Design and Baseline Characteristics of the Finerenone in ...
Patients andMethods:The Finerenone in Reduc- ing CV Mortality and Morbidity in Diabetic Kidney Disease. (FIGARO-DKD) trial aims to assess ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Finerenone (Kerendia) Gets FDA Nod for Chronic Kidney ...
With approval on July 9, finerenone became the first nonsteroidal mineralocorticoid receptor antagonist approved by the FDA for treatment of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Finerenone - Side Effects, Interactions, Uses, Dosage, Warnings
Finerenone is used in adults with chronic kidney disease related to diabetes mellitus type 2, to reduce the risk of:.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Finerenone Tablets (Kerendia) | Relias Media
Finerenone can be prescribed to lower the risk of sustained estimated glomerular filtration rate decline, cardiovascular death, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Bayer's finerenone meets primary goal in Phase III - The ...
The clinical data from FIGARO-DKD will be presented at an upcoming scientific meeting. BayerChronic kidney diseaseDiabetesDrug Trialfinerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Bayer's finerenone scores FDA priority review for chronic ...
Finerenone – also known as BAY 94-8862 – is a selective mineralocorticoid receptor antagonist (MRA). Overactivation of the mineralocorticoid ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Finerenone may delay onset of AFib in patient | EurekAlert!
Patients with chronic kidney disease and Type 2 diabetes who took the experimental drug finerenone were about 30% less likely to develop the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Finerenone (KERENDIA) Approved for Chronic Kidney ...
With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73finerenone — Freely Filtered, a NephJC Podcast
Tagged: diabetic nephropathy, diabetic kidney disease, aldosterone antagonist, finerenone, fidelio, bakris, burgner, waitzman, Sparks, topf.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74FIDELITY: Finerenone benefits patients with T2D across CKD ...
New data on using the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone to treat patients with type 2 diabetes and chronic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Finerenone Lowers Risks of Chronic Kidney Disease in ...
Researchers reported that patients who received finerenone had a lower risk of kidney failure or death from renal causes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76FINERENONE - Inxight Drugs
FINERENONE is a potent and selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Finerenone | Glucocorticoid Receptor | 陶术生物 - 陶素生化
Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Bayer Extends Clinical Development Program for Finerenone ...
Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Finerenone: First Approval - ResearchGate
Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid...
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. Kolkhof, Peter PhD * ; Delbeck, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81EMEA-001623-PIP01-14-M03 | European Medicines Agency
Public summary of the evaluation of a proposed paediatric investigation plan: Finerenone for treatment of chronic kidney disease (PDF/91.15 KB).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Finerenone reduces risk of cardiovascular events in patients ...
Bayer's finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Finerenone (Synonyms: BAY 94-8862) - Medchemexpress
Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Finerenone - Glucocorticoid Receptor - TargetMol
Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Cardiac Events With Type 2 Diabetes, Kidney Disease ...
Finerenone improved cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease versus placebo in a phase 3 trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Finerenone Provides CV, Renal Benefits in Diabetes Across ...
Finerenone reduces the risk for cardiovascular and renal outcomes in patients with type 2 diabetes who have mild chronic kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Finerenone: A Non-steroidal Mineralocorticoid Receptor ...
Targeting inflammation and fibrosis as a driver, the FIDELIO-DKD (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Finerenone Reduces New-Onset AF in Patients With CKD and ...
In patients with chronic kidney disease and type 2 diabetes, finerenone reduced new-onset atrial fibrillation or flutter risk.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Finerenone (Bayer) Market Overview and Drug Profile
Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Finerenone significantly reduced renal ... - PipelineReview.com
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Bayer announces FDA accepts NDA and grants priority review ...
Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that demonstrated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Bayer's big news: Finerenone gains FDA approval for patients ...
The FDA has approved finerenone for slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93European Society of Cardiology on Twitter: "#FIGARO-DKD ...
#FIGARO-DKD trial: finerenone reduces the risk of #cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94糖尿病腎病變的新療法- Finerenone - 艾維的醫學筆記站
一組接受實驗用藥- Finerenone,為FDA尚未批准的非類固醇礦物質皮質素拮抗 ... Effect of finerenone on chronic kidney disease outcomes in type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#95「腎」利的曙光——Finerenone - 每日頭條
此外,新一代非甾體鹽皮質激素受體拮抗劑(MR)也在糖尿病腎病(Diabetic Kidney Disease, DKD)適應症中嶄露頭角,其中Finerenone在2020年7月9日披露積極 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#96Finerenone, BAY 94-8862 | New Drug Approvals
Used as mineralocorticoid receptor antagonist for treating heart failure and diabetic nephropathy. SYNTHESIS. str1. Finerenone (INN, USAN) ( ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#97Finerenone - Report Store | Pharma intelligence
Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
finerenone 在 コバにゃんチャンネル Youtube 的最讚貼文
finerenone 在 大象中醫 Youtube 的精選貼文
finerenone 在 大象中醫 Youtube 的精選貼文